62nd Annual Meeting
Society of Thrombosis and Haemostasis Research

62. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)

„Thrombose- und Hämostaseforschung – das Rad dreht sich weiter“

Wien, 20. – 23. Februar 2018
Messe Wien – Congress Center, Austria  www.gth2018.org
# CONTENTS

- Invitation ............................................................... 2
- Organisation ......................................................... 3
- Presentation/Session Formats ................................. 5
- Preliminary Programme Grid .................................. 6
- Scientific Programme – Tuesday, February 20, 2018 .... 14
- Scientific Programme – Wednesday, February 21, 2018 ... 19
- Scientific Programme – Thursday, February 22, 2018 ... 27
- Scientific Programme – Friday, February 23, 2018 ....... 34
- Guidelines for Speakers & Preview Center ................. 36
- Grants, Awards and Prizes ...................................... 36
- Registration Information ...................................... 37
- General Congress Information ............................... 39
- Further Congress Information from A-Z ................. 40
- Hotel Information .................................................. 41
- Travel to Vienna .................................................... 42
- Terms & Conditions ............................................... 43
- Exhibitors ............................................................ 44
- Sponsors .............................................................. 45
Welcome to the Annual Meeting of the Society of Thrombosis and Haemostasis 2018!

We are delighted to announce the 62nd Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), which will be held in Vienna from February 20, 2018 until February 23, 2018.

“Thrombosis and Haemostasis Research - the wheel keeps on turning”. The motto of the conference pays tribute to the tremendous and everlasting progress in thrombosis and haemostasis research over the last years and in the years to come. An array of novel antithrombotic drugs and the revolutionary achievements in hemophilia treatment are only two examples for what has been happening in our field just recently.

We expect colleagues from around the world to meet in Vienna and discuss recent advances both in clinical and in basic research. Our program shall consist of traditional plenary and state-of-the-art lectures and oral and poster presentations, but shall also include formats, which allow a more intense interaction between audience and presenter.

“The wheel keeps on turning” also refers to a Viennese landmark, das “Riesenrad” ("the Giant Ferris Wheel" covers the front page of the program), located in close proximity to the conference venue. Do not miss a ride on the “Giant Ferris Wheel”, which will give you not only a spectacular view of the city of Vienna but weather permitting of the Alps in the West to the Carpathian Mountains in the East.

The congress language will be English to acknowledge the increasing number of attendees and lecturers from all over the world.

We sincerely hope that you will follow our invitation and we look forward to welcoming you in Vienna on the occasion of the 62nd Annual Meeting of the GTH.

Paul Alexander Kyrle
Sabine Eichinger
(Congress presidents)
PRESENTATION / SESSION FORMATS

Plenary Session
Seven plenary lectures in four plenary sessions will provide updates on the main topics of the congress; no discussion scheduled.

Debates
During GTH 2018, three debates will take place. Presentations will be based on questions and/or controversies proposed by the chairperson so to stimulate a lively debate.

Educational Lectures, Critical Management Decisions, How I manage, Spotlight, State of the Art
Each of these sessions will cover topics of general practical and clinical interest in an innovative way.

Meet the Expert Sessions
These sessions are targeted at our younger investigators, allowing them to meet leaders and well-known experts in the field. A short introduction by the expert will be followed by an interactive exchange of questions and a discussion. The Meet-the-Expert sessions run in parallel of four.

Oral Sessions
Several parallel sessions will provide abstract submitters with an opportunity to present their works in a lecture hall.

Poster Presentations
Posters will be on display from Wednesday, 21 February 2018, 12:00 until Friday, 23 February 2018, 12:00. Official poster presentations will take place on Wednesday, 21 February from 18:15-19:00. All presenters are asked to be at their poster for discussions during that time.

Workshops/Working Groups
Special workshops/working group meetings are scheduled throughout the entire congress on request. For reservation of small meeting rooms please contact the Exhibition/Sponsoring Office at gth2018@media.co.at.

Satellite/Lunch Symposia/Exhibition
According to the tradition of GTH meetings, there will be a set of interesting satellite symposia, partially planned as lunch symposia.
<table>
<thead>
<tr>
<th>TUESDAY</th>
<th>WEDNESDAY</th>
<th>THURSDAY</th>
<th>FRIDAY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:45</strong></td>
<td><strong>08:00</strong></td>
<td><strong>08:15</strong></td>
<td><strong>08:30</strong></td>
</tr>
<tr>
<td><strong>08:45</strong></td>
<td><strong>09:00</strong></td>
<td><strong>09:15</strong></td>
<td><strong>09:30</strong></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td><strong>10:15</strong></td>
<td><strong>10:30</strong></td>
<td><strong>10:45</strong></td>
</tr>
<tr>
<td><strong>11:00</strong></td>
<td><strong>11:15</strong></td>
<td><strong>11:30</strong></td>
<td><strong>11:45</strong></td>
</tr>
<tr>
<td><strong>12:00</strong></td>
<td><strong>12:15</strong></td>
<td><strong>12:30</strong></td>
<td><strong>12:45</strong></td>
</tr>
<tr>
<td><strong>13:00</strong></td>
<td><strong>13:15</strong></td>
<td><strong>13:30</strong></td>
<td><strong>13:45</strong></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td><strong>14:15</strong></td>
<td><strong>14:30</strong></td>
<td><strong>14:45</strong></td>
</tr>
<tr>
<td><strong>15:00</strong></td>
<td><strong>15:15</strong></td>
<td><strong>15:30</strong></td>
<td><strong>15:45</strong></td>
</tr>
<tr>
<td><strong>16:00</strong></td>
<td><strong>16:15</strong></td>
<td><strong>16:30</strong></td>
<td><strong>16:45</strong></td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td><strong>17:15</strong></td>
<td><strong>17:30</strong></td>
<td><strong>17:45</strong></td>
</tr>
<tr>
<td><strong>18:00</strong></td>
<td><strong>18:15</strong></td>
<td><strong>18:30</strong></td>
<td><strong>18:45</strong></td>
</tr>
<tr>
<td><strong>19:00</strong></td>
<td><strong>19:15</strong></td>
<td><strong>19:30</strong></td>
<td><strong>19:45</strong></td>
</tr>
<tr>
<td><strong>20:00</strong></td>
<td><strong>20:15</strong></td>
<td><strong>20:30</strong></td>
<td><strong>20:45</strong></td>
</tr>
</tbody>
</table>
### Preliminary Programme Grid

#### Tuesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td>Schubert 6</td>
<td>Meet the expert: The interplay between the complement and the coagulation system</td>
</tr>
<tr>
<td>08:00</td>
<td>Gallerie 9-10</td>
<td>BDDH (Berufsverband der Deutschen Hämostaseologen e.V.)</td>
</tr>
<tr>
<td>08:15</td>
<td>Business Suite 1</td>
<td>Ständige Kommission Labor</td>
</tr>
<tr>
<td>08:45</td>
<td>Exhibition Area</td>
<td>Poster &amp; Exhibiton</td>
</tr>
</tbody>
</table>

#### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td>Plenary Hall</td>
<td>State of the Art von Willebrand factor revisited</td>
</tr>
<tr>
<td>08:00</td>
<td>Stolz 1</td>
<td>Plenary Session RNA Therapeutics in cardiovascular disease</td>
</tr>
<tr>
<td>08:15</td>
<td>Stolz 2</td>
<td>Antithrombotic treatment after coronary intervention: which drugs and for how long?</td>
</tr>
<tr>
<td>08:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium CSL 2</td>
</tr>
<tr>
<td>08:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Pfizer Pharma</td>
</tr>
<tr>
<td>09:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Roche/Chugai</td>
</tr>
<tr>
<td>09:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Alexion</td>
</tr>
<tr>
<td>09:30</td>
<td>Schubert 1-3</td>
<td>Educational Fibrin, Fibrinolysis and beyond</td>
</tr>
<tr>
<td>09:45</td>
<td>Schubert 4,5</td>
<td>Educational Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>10:00</td>
<td>Schubert 1-3</td>
<td>Educational Novel approaches for the treatment of bleeding disorders</td>
</tr>
<tr>
<td>10:15</td>
<td>Schubert 4,5</td>
<td>Educational Coagulation activation in critically ill patients</td>
</tr>
<tr>
<td>10:30</td>
<td>Schubert 1-3</td>
<td>Debate Should all patients with unprovoked VTE receive lifelong anticoagulation</td>
</tr>
<tr>
<td>10:45</td>
<td>Schubert 4,5</td>
<td>Spotlight Pediatric stroke</td>
</tr>
<tr>
<td>11:00</td>
<td>Schubert 1-3</td>
<td>State of the Art The big bang of clotting: how it all starts</td>
</tr>
<tr>
<td>11:15</td>
<td>Schubert 4,5</td>
<td>Critical Management Decisions Hemophilia</td>
</tr>
<tr>
<td>11:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Bayer Kovaltry</td>
</tr>
<tr>
<td>11:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Pfizer/BMS</td>
</tr>
<tr>
<td>12:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Stago</td>
</tr>
<tr>
<td>12:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium CSL 2</td>
</tr>
<tr>
<td>12:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Pfizer Pharma</td>
</tr>
<tr>
<td>12:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Roche/Chugai</td>
</tr>
<tr>
<td>13:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Alexion</td>
</tr>
<tr>
<td>13:15</td>
<td>Schubert 4,5</td>
<td>Educational Fibrin, Fibrinolysis and beyond</td>
</tr>
<tr>
<td>13:30</td>
<td>Schubert 1-3</td>
<td>Educational Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>13:45</td>
<td>Schubert 4,5</td>
<td>Educational Novel approaches for the treatment of bleeding disorders</td>
</tr>
<tr>
<td>14:00</td>
<td>Schubert 1-3</td>
<td>Educational Coagulation activation in critically ill patients</td>
</tr>
<tr>
<td>14:15</td>
<td>Schubert 4,5</td>
<td>Debate Should all patients with unprovoked VTE receive lifelong anticoagulation</td>
</tr>
<tr>
<td>14:30</td>
<td>Schubert 1-3</td>
<td>Spotlight Pediatric stroke</td>
</tr>
<tr>
<td>14:45</td>
<td>Schubert 4,5</td>
<td>State of the Art The big bang of clotting: how it all starts</td>
</tr>
<tr>
<td>15:00</td>
<td>Schubert 1-3</td>
<td>Critical Management Decisions Hemophilia</td>
</tr>
<tr>
<td>15:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Bayer Kovaltry</td>
</tr>
<tr>
<td>15:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Pfizer/BMS</td>
</tr>
<tr>
<td>15:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Stago</td>
</tr>
<tr>
<td>16:00</td>
<td>Schubert 1-3</td>
<td>Educational Fibrin, Fibrinolysis and beyond</td>
</tr>
<tr>
<td>16:15</td>
<td>Schubert 4,5</td>
<td>Educational Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>16:30</td>
<td>Schubert 1-3</td>
<td>Educational Novel approaches for the treatment of bleeding disorders</td>
</tr>
<tr>
<td>16:45</td>
<td>Schubert 4,5</td>
<td>Educational Coagulation activation in critically ill patients</td>
</tr>
<tr>
<td>17:00</td>
<td>Schubert 1-3</td>
<td>Debate Should all patients with unprovoked VTE receive lifelong anticoagulation</td>
</tr>
<tr>
<td>17:15</td>
<td>Schubert 4,5</td>
<td>Spotlight Pediatric stroke</td>
</tr>
<tr>
<td>17:30</td>
<td>Schubert 1-3</td>
<td>State of the Art The big bang of clotting: how it all starts</td>
</tr>
<tr>
<td>17:45</td>
<td>Schubert 4,5</td>
<td>Critical Management Decisions Hemophilia</td>
</tr>
<tr>
<td>18:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Bayer Kovaltry</td>
</tr>
<tr>
<td>18:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Pfizer/BMS</td>
</tr>
<tr>
<td>18:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Stago</td>
</tr>
<tr>
<td>18:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium CSL 2</td>
</tr>
<tr>
<td>19:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Pfizer Pharma</td>
</tr>
<tr>
<td>19:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Roche/Chugai</td>
</tr>
<tr>
<td>19:30</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Alexion</td>
</tr>
<tr>
<td>19:45</td>
<td>Schubert 4,5</td>
<td>Educational Fibrin, Fibrinolysis and beyond</td>
</tr>
<tr>
<td>20:00</td>
<td>Schubert 1-3</td>
<td>Educational Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>20:15</td>
<td>Schubert 4,5</td>
<td>Educational Novel approaches for the treatment of bleeding disorders</td>
</tr>
<tr>
<td>20:30</td>
<td>Schubert 1-3</td>
<td>Educational Coagulation activation in critically ill patients</td>
</tr>
<tr>
<td>20:45</td>
<td>Schubert 4,5</td>
<td>Debate Should all patients with unprovoked VTE receive lifelong anticoagulation</td>
</tr>
<tr>
<td>21:00</td>
<td>Schubert 1-3</td>
<td>Spotlight Pediatric stroke</td>
</tr>
<tr>
<td>21:15</td>
<td>Schubert 4,5</td>
<td>State of the Art The big bang of clotting: how it all starts</td>
</tr>
<tr>
<td>21:30</td>
<td>Schubert 1-3</td>
<td>Critical Management Decisions Hemophilia</td>
</tr>
<tr>
<td>21:45</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Bayer Kovaltry</td>
</tr>
<tr>
<td>22:00</td>
<td>Schubert 1-3</td>
<td>Industry Symposium Pfizer/BMS</td>
</tr>
<tr>
<td>22:15</td>
<td>Schubert 4,5</td>
<td>Industry Symposium Stago</td>
</tr>
</tbody>
</table>

---

### Scientific Session

- Debates
- Workshops
- Plenary Sessions
- Oral Communications & Poster
<table>
<thead>
<tr>
<th>Time</th>
<th>Plenary Hall</th>
<th>Stadt 1</th>
<th>Stadt 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Meet the expert**

- Schubert 1-3: Meet the expert
- Schubert 4,5: How to run a coagulation laboratory
- Schubert 6: Antithrombotic therapy in children

**Oral communications**

- Best Abstracts
- Extracellular Vesicles

**Educational**

- Cancer associated thrombosis
- Platelets and immunology
- APLA

**Plenary Session**

- Regulation of Fibrin Clot Structure and Clinical Implications
- Hemophilia treatment in 2018: What will change – what will remain
- 12:20 - 13:00: Closing Ceremony
10:30 – 12:00  Ständige Kommission Hämophilie
Schubert 1-3

12:00 – 13:30  Arbeitsgruppe womens health
Schubert 4,5

Thromboseprophylaxe in der Schwangerschaft: Neue Aspekte?!
Chairs: H. Rott (Duisburg, DE)
R. Bauersachs (Darmstadt, DE)

Thromboseprophylaxe bei schwerer Thrombophilie in der Schwangerschaft. Welche Rolle spielt die Familienanamnese?
R. Zotz (Duesseldorf, DE)

Thromboseprophylaxe bei heterozygoter Faktor V/II-Mutation. Wird das Risiko überbewertet?
F. Bergmann (Hannover, DE)

Antikoagulation beim Antiphospholipid-Nachweis/-Syndrom. Gibt es verschiedene Risikoklassen?
U. Scholz (Leipzig, DE)

12:00 – 13:30  Ständige Kommission Pädiatrie
Schubert 6
14:00 – 15:00 State-of-the-Art: Microvesicles - their role in cardiovascular disease
Schubert 4,5
Microvesicles - what do we measure, the road towards standardization
Francoise Dignat-George (Marseille, FR)
Microvesicles in vascular homeostasis and disease
Johann Wojta (Vienna, AT)

15.15 – 16.45 Satellite Symposium – CSL Behring
Schubert 1-3
Moderne Faktorkonzentrate in der Hämophilie – Lessons learned
Chairs: Johannes Oldenburg (Bonn, DE) Ingrid Pabinger-Fasching (Vienna, AT)
AFSTYLA® - Update Klinisches Studienprogramm
Ingrid Pabinger-Fasching (Vienna, AT)
AFSTYLA® – Case Reports Erwachsene
Georg Goldmann (Bonn, DE)
AFSTYLA® – Case Reports Kinder
Christoph Bidlingmaier (Munich, DE)
IDELVION® – Update Klinisches Studienprogramm
Hans-Jürgen Laws (Düsseldorf, DE)
IDELVION® – Case Reports Erwachsene
Christian Pfrepper (Leipzig, DE)
IDELVION® – Case Reports Kinder
Carmen Escuriola-Ettingshausen (Mörfelden-Walldorf, DE)
Neue Entwicklungen in der Hämophilie bei CSL Behring
Thomas Weimer (Marburg, DE)

14:00 – 15:00 Critical management decisions during pregnancy
Plenary Hall
Management of antithrombin deficiency
Susan Halimeh (Duisburg, DE)
Management of women with mechanical heart valves
Birgit Linnemann (Frankfurt am Main, DE)
Management of women with ITP
Francesco Rodeghiero (Vicenza, IT)

14:00 – 15:00 Spotlight: Thrombosis and haemostasis in the era of migration
Stolz 1
Coagulation activation in hemoglobinopathies
Nigel Key (Chapel Hill, US)
Rare bleeding disorders
Gili Kenet (Tel Hashomer, IL)

15.15 – 16.45 Satellite Symposium – Aspen
Schubert 4,5
Vom Verdacht zur Therapie – wie manage ich die HIT richtig?
Chair: Andreas Greinacher (Greifswald, DE)
Begrüßung
Andreas Greinacher (Greifswald, DE)
Update HIT – was gibt es Neues?
Andreas Greinacher (Greifswald, DE)
HIT-Behandlung – eine zunehmend sektorenübergreifender Auftrag!?
Jürgen Kosielnny (Berlin, DE)
Modernes HIT-Management in der Klinik – eine interdisziplinäre Aufgabe?
Kathleen Selleng (Greifswald, DE)
Take-Home Messages und Verabschiedung
Andreas Greinacher (Greifswald, DE)
WEDNESDAY, FEBRUARY 21, 2018

08:00 – 08:30 Meet the expert sessions
Stolz 2
Diagnosis, classification and management of the postthrombotic syndrome
Viola Hach-Wunderle (Frankfurt am Main, DE)
Schubert 4,5
Methods in clinical research
Christoph Male (Vienna, AT)
Schubert 6
The interplay between the complement and coagulation system
Tom Eirik Mollnes (Oslo, NO)
Stolz 1
Bleeding assessment tools
Francesco Rodeghiero (Vicenza, IT)

08:45 – 09:45 Oral communications
Stolz 1
Stolz 2
Schubert 1-3
Schubert 4,5

08:45 – 10:15 Berufsverband der Deutschen Hämostaseologen e.V. (BDDH)
Schubert 6
Update Antikorruptionsgesetz
Chairs: J. Koscielny (Berlin, DE)
G. Kappert (Duisburg, DE)
Stand 2018
G. Buchheim (Berlin, DE)
Anschließend Mitgliederversammlung des BDDH e.V.

08:45 – 10:15 Ständige Kommission Labor
Galerie 9-10

10:15 – 11:00 Debate: Is there still a role for aspirin in cardiovascular disease?
Stolz 2
Yes, never change a winning team
Tobias Geisler (Tübingen, DE)
No, we have already seen enough bleeding
Andreas Zirlik (Freiburg, DE)
12:30 – 14:00 Satellite Symposium – Roche/Chugai
Schubert 1-3
Haemophilia A therapy - a step forward towards innovation
Chairs: Johannes Oldenburg (Bonn, DE)
        Ingrid Pabinger-Fasching (Vienna, AT)
Introduction
Johannes Oldenburg (Bonn, DE), Ingrid Pabinger-Fasching (Vienna, AT)
Science Slam: Energie — Wie verschwendet man etwas, das nicht weniger werden kann?
Martin Buchholz (Braunschweig, DE)
Mode of Action and Interactions of the bispecific antibody Emicizumab
Midori Shima (Nara, JP)
Monitoring of Emicizumab
Michael Spannagl (Munich, DE)
Results on the Efficacy and Safety of Emicizumab in HAVEN 1 and HAVEN 2 trial
Johannes Oldenburg (Bonn, DE)
Summary
Johannes Oldenburg (Bonn, DE), Ingrid Pabinger-Fasching (Vienna, AT)

10:15 – 11:00 Debate: Is there a place for endovascular therapy of venous thrombosis after ATTRACT?
Stolz 1
Yes, let’s have a closer look at the data
Oliver Schlager (Vienna, AT)
No, with DOACs we have an optimal therapy
Sebastian Schellong (Dresden, DE)

10:00 – 11:15 Spotlight: Angiogenesis - The good, the bad and the ugly?
Schubert 4,5
Angiogenesis in the ischemic heart - new vessels where they are needed
Johannes Waltenberger (Münster, DE)
Dynamic Cellular Arrangement during vascular remodelling and plaque vascularization
Paul Quax (Leiden, NL)

10:00 – 11:15 State-of-the-Art: Von Willebrand factor revisited
Plenary Hall
Regulation of thrombus formation by gut microbiota
Christoph Reinhardt (Mainz, DE)
Von Willebrand factor - more than a carrier of FVIII
Anne Goodeve (Sheffield, UK)

11:15 – 12:15 Plenary Session
Plenary Hall
RNA therapeutics for cardiovascular disease
Stefanie Dimmel (Frankfurt am Main, DE)
Antithrombotic treatment after coronary intervention – which drugs and for how long?
Christoph Bode (Freiburg, DE)
12:30 – 14:00 Satellite Symposium – CSL Behring
Stolz 1

Hämorrhagische Diathesen – Klinische Relevanz seltener Gerinnungsstörungen

Chairs: Angela Huth-Kühne (Heidelberg, DE)
Karin Kurnik (Munich, DE)

Inhibitoren – worauf sollte man achten?
Relevanz von Antikörper – Untersuchungen
Christoph Königs (Frankfurt, DE)

Gestörte Wundheilungsprozesse bei Hämophilie - Erste Erkenntnisse
Jan Pilch (Homburg, DE)

Das von Willebrand Syndrom immer noch häufig unerkannt
Rudolf Schwarz (Linz, AT)

Das erworbene von Willebrand Syndrom im Zusammenhang mit Ventricular Assist Device
Barbara Zieger (Freiburg, DE)

12:30 – 14:00 Satellite Symposium – Pfizer Pharma
Stolz 2

Das nächste Level - Innovation und Fortschritt in der Hämophiliebehandlung

Chairs: Wolfgang Miesbach (Frankfurt, DE)
Freimut Schilling (Stuttgart, DE)

Individuelle Prophylaxe – von der Theorie zur Praxis
Heinrich Richter (Münster, DE)

Papierdokumentation war gestern – Real Life Erfahrung mit Haemoassist 2
Georg Goldmann (Bonn, DE)

Neue Behandlungsansätze - ein Blick in die Zukunft
Andreas Tiede (Hannover, DE)

14:15 – 15:15 Educational: Coagulation activation in critically ill patients
Schubert 4,5

Disseminated intravascular coagulation
Bernd Jilma (Vienna, AT)

Transfusion in patients with liver disease: treat patients instead of lab values
Johannes Antonius Lisman (Groningen, NL)

14:15 – 15:15 Educational: Fibrin, fibrinolysis and beyond
Stolz 1

Factor XIII: Structure and function
Verena Schröder (Berne, CH)

Treatment of acute PE – to lyse or not to lyse
Cecilia Becattini (Perugia, IT)

Schubert 1-3

Non-replacement alternatives for treatment of bleeding disorders
Carmen Escuriola-Ettingshausen (Mörfelden-Walldorf, DE)

Haemophilia – which concentrate for which patient?
Ingrid Pabinger-Fasching (Vienna, AT)

14:15 – 15:15 Educational: Thrombotic thrombocytopenic purpura
Stolz 2

Pathomechanisms of thrombotic microangiopathy
Marie Scully (London, UK)

New aspects in the treatment of TTP
Johanna A. Kremer Hovinga (Berne, CH)
**Debate: Should all patients with unprovoked VTE receive lifelong anticoagulation**

Yes, watch out for the recurrence risk  
Rupert Bauersachs (Darmstadt, DE)

No, it's a dangerous burden  
Geert Jan Geersing (Utrecht, NL)

**State-of-the-Art: The big bang of clotting - how it all starts**

Polyphosphates and platelets  
Thomas Renné (Stockholm, SE)

Modern concepts of coagulation activation  
James H. Morrissey (Ann Arbor, US)

**Spotlight: Paediatric stroke**

Update 2018  
Maja Steinlin (Bern, CH)

Paediatric stroke network  
Martin Olivieri (Munich, DE)

Thrombectomy in paediatric stroke  
Elke Gizewski (Innsbruck, AT)

**Critical management decisions - haemophilia**

Haemophilia and cardiovascular interventions  
Robert Klamroth (Berlin, DE)

Management of acquired coagulation inhibitors  
Paul Knöbl (Vienna, AT)
## SCIENTIFIC PROGRAMME  WEDNESDAY, FEBRUARY 21, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:45 – 18:15 | Satellite Symposium  
Pfizer Pharma / BMS  
Stolz 2 |
|               | Orale Antikoagulation 2018: Venöse Thromboembolie - handhabbar aber nicht zu unterschätzen! |
|               | Chairs: Rupert Bauersachs (Darmstadt, DE)  
                            Paul Alexander Kyrle (Vienna, AT) |
|               | Tumorassozierte Thromboembolien - Was bringt uns die Zukunft? |
|               | Chairs: Inge Scharrer (Mainz, DE)  
                            Björn Habermann (Frankfurt, DE) |
|               | Thrombophilie - Was hat sich bewährt und was gibt es Neues? |
|               | Chairs: Rupert Bauersachs (Darmstadt, DE) |
| 08:15 – 09:45 | Muskulo-Skelettaler Arbeitskreis Hämophilie  
Schubert 6 |
|               | S2k-Leitlinie Synovitis bei Hämophilie  
Chairs: Inge Scharrer (Mainz, DE)  
                            Björn Habermann (Frankfurt, DE) |
|               | Einführung  
Björn Habermann (Frankfurt, DE) |
|               | Epidemiologie, Pathogenese und Klinik der Synovitis  
Thomas Hilberg (Wuppertal, DE)  
                            Hans-Hermann Brackmann (Bonn, DE) |
|               | Diagnostik der Synovitis - Körperliche Untersuchung und Labor  
Axel Seuser (Bonn, DE)  
                            Inge Scharrer (Mainz, DE) |
|               | Diagnostik der Synovitis – Apparative Diagnostik  
Michael Sigl-Kräztig (Ulm, DE)  
                            Michael Püsken (Cologne, DE)  
                            Barbara Boddenberg-Pätzold (Cologne, DE) |
|               | Therapie der Synovitis – Medikamentös  
Susan Halimeh (Duisburg, DE)  
                            Sylvia Horneff (Bonn, DE)  
                            Johannes Oldenburg (Bonn, DE) |
|               | Therapie der Synovitis – Konservativ  
Marc Rosenthal (Duisburg, DE)  
                            Sebastian Weinspach (Duesseldorf, DE) |
|               | Therapie der Synovitis – Interventionell  
Barbara Boddenberg-Pätzold (Cologne, DE)  
                            Björn Habermann (Frankfurt, DE) |
|               | Diskussion und Abschlussbemerkungen  
Alle, Björn Habermann (Frankfurt, DE) |
SCIENTIFIC PROGRAMME

Thursday, February 22, 2018

08:30 – 09:30
Oral communications
Stolz 1
Stolz 2
Schubert 1-3
Schubert 4,5

10:00 – 11:00
How I manage: Thrombosis
Plenary Hall
Chronic thromboembolic pulmonary hypertension
Irene Lang (Vienna, AT)
Thrombosis at unusual sites
Walter Ageno (Varese, IT)

10:00 – 11:00
State-of-the-Art: Critical aspects in the use of DOACS
Schubert 1-3
The role of laboratory tests
Lorenzo Alberio (Lausanne, CH)
Can DOACS be used in cancer patients?
Anne Angelillo-Scherrer (Berne, CH)
Reversal strategies
Thomas Gary (Graz, AT)

10:00 – 11:00
State-of-the-Art: Platelet disorders in children
Schubert 4, 5
Inherited disorders of platelet function: Update 2018
Walter Kahr (Ontario, CA)
Thrombocytosis in children
Clemens Stockklausner (Garmisch-Partenkirchen, DE)

10:00 – 11:00
State-of-the-Art: Novel aspects of leukocyte biology in atherosclerosis
Stolz 2
Neutrophils in atherosclerosis
Oliver Söhnlein (Munich, DE)
Immune checkpoints in atherosclerosis
Johan Kuiper (Leiden, NL)

11:15 – 12:15
Plenary Session
Plenary Hall
Renaissance of the contact system – a target for antithrombotic treatment
Jeff Weitz (Hamilton, CA)
Diagnostic imaging in venous thromboembolism
Menno V. Huisman (Leiden, NL)

12:30 – 14:00
Satellite Symposium – Octapharma
Stolz 1
Nuwig® (Human-cl rh FVIII): Recent updates and Real-World Experience
Chairs:
Manuela Albisetti (Zurich, CH)
Cihan Ay (Vienna, AT)
Nuwig®: Human FVIII with many faces - Understanding patient motivation
Georg Goldmann (Bonn, DE)
Surgical prophylaxis using Nuwig® - From clinical data to clinical practice
Natascha Marquardt (Bonn, DE)
Continuous infusion for surgical prophylaxis - Concepts and clinical experience with simoctocog alfa from the Oslo center
Pål André Holme (Oslo, NO)
PK-adjusted individualised therapy - Practical implications of full PK (NuPreviq) and population based approach (WAPPS-hemo)
Saskia Gottstein (Berlin, DE)
12:30 – 14:00 Satellite Symposium – Bayer

Schubert 1-3

Umfassendes Thrombosemanagement mit NOACs – Wo stehen wir?
Chairs: Sylvia Haas (Munich, DE), Sabine Eichinger-Hasenauer (Vienna, AT)

Begrüßung
Sabine Eichinger-Hasenauer (Vienna, AT)

Venöse Thromboembolien – Daten aus dem Alltag
Jan Beyer-Westendorf (Dresden, DE)

Verlängerte Erhaltungstherapie – Was tun nach 3, 6 oder 12 Monaten?
Rupert Bauersachs (Darmstadt, DE)

Antikoagulation bei Patienten mit koronarer Herzkrankheit oder peripherer arterieller Verschlusskrankheit – Praxis und Studienlage
Christoph Bode (Freiburg, DE)

Venöse Thromboembolien bei onkologischen Patienten – Eine Herausforderung in der Praxis
Sabine Eichinger-Hasenauer (Vienna, AT)

Board Diskussion
Sabine Eichinger-Hasenauer (Vienna, AT), Jan Beyer-Westendorf (Dresden, DE), Rupert Bauersachs (Darmstadt, DE), Christoph Bode (Freiburg, DE), Sylvia Haas (Munich, DE)

12:30 – 14:00 Satellite Symposium – Swedish Orphan Biovitrum

Schubert 4,5

GTH mal anders: Gelenke, Talspiegel, Halbwertszeitverlängerung – Welche Fragen haben unsere Patienten?
Chair: Ingrid Pabinger-Fasching (Vienna, AT)

Eine interaktive Podiumsdiskussion
Inga Hegemann (Zurich, CH), Bettina Kemkes-Matthes (Gießen, DE), Robert Klamroth (Berlin, DE), Christoph Königs (Frankfurt, DE), Johannes Oldenburg (Bonn, DE), Michael Spannagl (Munich, DE), Andreas Tiede (Hannover, DE)

14:15 – 16:15 GTH Mitgliederversammlung

Plenary Hall

16:45 – 18:15 Satellite Symposium – Shire

Stolz 2

Das passende Molekül für den individuellen Patienten - Part 1 - Halbwertszeit-verlängerter FVIII
Chair: Werner Streif (Innsbruck, AT)

BAX855 – Das FVIII-Molekül mit verlängerter Halbwertszeit
Werner Streif (Innsbruck, AT)

Praktische Erfahrungen aus klinischen Studien
Carmen Escuriola-Ettingshausen (Mörfelden-Walldorf, DE)

Zwei Jahre Produkterfahrung – Real World-Daten aus USA
Rebecca Kruse-Jarres (Seattle, US)

Personalisierung mit myPKFiT
Georg Goldmann (Bonn, DE)

Panel Discussion: Personalisierung der FVIII-Substitutionstherapie

Satellite Symposium – Shire

Stolz 2
**Satellite Symposium – Biotest**

**Stolz 1**

16:45 – 18:15

*Die Hämostase - ein Aspekt des Lebens*
Chair: Ingrid Pabinger-Fasching (Vienna, AT)

*Der optimal Start ins Leben*
Manuela Albisetti (Zurich, CH)

*Wie Kindheit und Jugend gelingen*
Marco Wehr (Tübingen, DE)

*Mit welcher Ernährung gesund durchs Leben?*
Udo Pollmer (Gemmingen, DE)

*Geistig fit bis ins hohe Alter*
Jule Specht (Berlin, DE)

---

**Satellite Symposium – Daiichi Sankyo**

**Schubert 1-3**

16:45 – 18:15

*Sicherheitsaspekte in der antithrombotischen Therapie aktuell.*

Chair: Sabine Eichinger-Hasenauer (Vienna, AT)
Hanno Riess (Berlin, DE)

**Begrüßung**
Hanno Riess (Berlin, DE)

*VTE bei Krebs-Patienten – Herausforderungen zwischen Leitlinien und klinischem Alltag*
Cihan Ay (Vienna, AT)

*Neue Perspektiven durch aktuelle Studienergebnisse? Hokusai VTE-cancer*
Jan Beyer-Westendorf (Dresden, DE)

*Management spezieller Patienten – Do’s und Don’ts aus Sicht des Hämostaseologen*
Florian Langer (Hamburg, DE)

**Zusammenfassung**
Sabine Eichinger-Hasenauer (Vienna, AT)

---

**Satellite Symposium – LFB**

**Schubert 4,5**

16:45 – 18:15

*Panta rhei – Das von Willebrand Syndrom und der kongenitale Fibrinogenmangel [Panta rhei von Willebrand disease and congenital fibrinogen deficiency]*

Chair: Michael Spannagl (Munich, DE)
Wolfgang Miesbach (Frankfurt, DE)

**Begrüßung**
Michael Spannagl (Munich, DE)

*Specific treatment of von Willebrand disease in different stages of life*
Jenny Goudemand (Lille, FR)

*Kongenitales von Willebrand Syndrom in speziellen klinischen Situationen*
Wolfgang Miesbach (Frankfurt, DE)

*Management des kongenitalen Fibrinogenmangels*
Carl-Erik Dempfle (Mannheim, DE)

**Zusammenfassung & Diskussion**
SCIENTIFIC PROGRAMME  
FRIDAY, FEBRUARY 23, 2018

07:45 – 08:15  Meet the expert sessions
Schubert 6  Antithrombotic therapy in children
Werner Streif (Innsbruck, AT)
Stolz 2  Periinterventional management of antithrombotic therapy
Ansgar Weltermann (Linz, AT)
Stolz 1  Role of tissue factor in thrombus formation
Henri Versteeg (Leiden, NL)
Schubert 4,5  How to run a coagulation laboratory
Peter Quehenberger (Vienna, AT)

08:30 – 09:30  Oral communications
Stolz 1
Stolz 2
Schubert 1-3
Schubert 4,5

10:00 – 11:00  Educational: Platelets and immunology
Stolz 1  Does heparin-induced thrombocytopenia become extinct?
Andreas Greinacher (Greifswald, DE)
Management of refractory ITP
Drew Provan (London, UK)

10:00 – 11:00  Educational: cancer-associated thrombosis
Plenary Hall  Cancer and thrombosis – thrombosis and cancer: pathomechanisms of a Janus-faced disease
Anna Falanga (Bergamo, IT)
Challenging aspects in the management of CAT
Cihan Ay (Vienna, AT)

10:00 – 11:00  Educational: Thrombosis - pathomechanisms and management
Schubert 1-3  Immunothrombosis
Christoph Binder (Vienna, AT)
Management of venous thromboembolism
Henri Bounameaux (Geneva, CH)

10:00 – 11:00  Educational: Antiphospholipid syndrome
Stolz 2  Pathomechanisms: an update for clinicians and scientists
Katrien Devreese (Gent, BE)
A guide to diagnosis and treatment
Thomas Lee Ortel (Durham, US)

11:15 – 12:15  Plenary Session
Plenary Hall  Regulation of fibrin clot structure and its clinical implications
Robert Ariens (Leeds, UK)
Haemophilia treatment in 2018: What will change – what will remain?
Flora Peyvandi (Milan, IT)

12:20 – 13:00  Closing Ceremony
Plenary Hall
GUIDELINES FOR SPEAKERS & PREVIEW CENTRE

Presentation slides are to be prepared in English language only. The preview centre will be located across from the registration desks. Only PowerPoint presentations are accepted. All presentations need to be prepared in 4:3 format.

Speakers should deliver and view/check their presentations at the preview centre at least two hours prior to the start of the respective session. For sessions starting in the morning, presentations should be delivered on the previous day.

In order to avoid any delays, speakers are kindly requested to hand in their presentations on a USB stick. Your PowerPoint presentation will be transferred to the congress server in the preview centre and will be available for you on the laptop present in the session at the speaker’s lectern in the session room.

If you wish to bring your own laptop, it is crucial to make this known in the preview centre three hours in advance for organisational reasons. Speakers are not permitted to take PowerPoint presentations directly to the technical assistant in the session rooms.

At the preview centre, work stations are available to make final changes or additions to presentations. Technical staff is present to assist you if necessary.

In the lecture rooms, presentations will be projected from a projector to the screen. Double projections are not possible.

Please locate your session room in due time. Please be in your session room at least 15 minutes prior to the start of the session.

GRANTS, AWARDS AND PRIZES

The GTH confers a number of awards and grants. The recipients will be announced during the GTH 2018 opening ceremony on Tuesday, February 20, 2018 in Vienna, Austria.

For more information on GTH Awards, please visit the society website: www.gth2018.org Travel grants of € 300.– each will be awarded to the authors of the best abstracts, according to reviewing results.

REGISTRATION INFORMATION

Please register through the online registration process available at www.gth2018.org. To benefit from the early bird registration fees, payments have to be made by Monday, December 18, 2017 latest. The date of the remittance order (as stamped on the slip) will be decisive for the early bird registration.

Registration Fees
All prices are stated in Euros [€].

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>€ 290.–</td>
<td>€ 350.–</td>
<td>€ 165.–</td>
</tr>
<tr>
<td>Non-Member</td>
<td>€ 350.–</td>
<td>€ 405.–</td>
<td>€ 195.–</td>
</tr>
<tr>
<td>PhD Student, Nurse, MTA, Physician in Training, Retired Member</td>
<td>€ 140.–</td>
<td>€ 160.–</td>
<td>€ 105.–</td>
</tr>
<tr>
<td>Student</td>
<td>€ 45.–</td>
<td>€ 45.–</td>
<td>€ 35.–</td>
</tr>
</tbody>
</table>

The registration fee includes:

- congress documentation (name badge, congress app incl. programme, programme booklet, scientific abstracts online)
- admission to scientific sessions as well as industry organised sessions
- admission to the industry exhibition
- attendance at the welcome reception on Tuesday, February 20, 2018 in the exhibition area

Tickets for the official networking evening at the Rathauskeller can be purchased during the registration process.
Price: € 70 for members and non-members
- € 40 reduced fee for students, PhD students, MTA and nursing staff

Member Fees
Member fees apply to individual members of GTH only. Member registrations will be checked on a regular basis.

PhD student, MTA, nursing staff, physician in training, student
To verify your status, a written confirmation from your chairman, head of department or programme director is required.
Please note that registrations can only be accepted via online registration and confirmed upon receipt of full payment. As soon as the Organising Secretariat has received your payment, a letter of confirmation will be emailed.
The date of the remittance order (as stamped on the slip) will be decisive for the early and regular registration fee.
Please present your letter of confirmation at the registration desk upon arrival.
REGISTRATION INFORMATION

Terms & Conditions
Deadline for pre-registration is Friday, February 16, 2018. For payment/registration after this date, your confirmation will be available on-site at the registration counter. On-site registration is possible throughout the entire congress during the opening hours of the registration counter. Cancellations must be made in writing to the congress secretariat, Mondial Congress & Events. If received before Monday, December 18, 2017, all fees, except for a cancellation charge of € 40,– will be refunded. No refunds will be made after this date. For name changes and replacements a handling fee of € 25,– will be charged.

Group Registrations (10 or more registrations)
Group registrations are done via individual forms and agreements. For group registrations, we kindly ask you to contact the Congress Secretariat to arrange details. Please note that the deadline for group registrations is on Friday, January 26, 2018.

Mondial Congress & Events
Operngasse 20b
1040 Vienna, Austria
Tel.: +43 1 58804-0
Fax: +43 1 58804-185
e-mail: gth2018@mondial-congress.com

Official Italian Agency
Once the scientific programme is available, the organisers will appoint AIM GROUP INTERNATIONAL – AIM Education S.r.l., located at Via Giuseppe Ripamonti nr. 129, 20141 Milan, Italy as official Italian agency to collect all delegate applications from Italian pharmaceutical companies and file them with the AIFA in compliance with its Legislative Order no 219/06, art. 124, regulating the industrial contributions to foreign congresses.

Confirmation & Payment
Upon receipt of the online registration and the corresponding payment, each participant will receive a confirmation form, which also serves as receipt. Please present this confirmation at the registration counter when picking up your congress material. When registering for the congress, please arrange the payment of your registration fee and any other costs according to the instructions in the online registration process. You can pay by credit card (Visa, MasterCard, AMEX and Diners will be accepted). The Congress Office recommends secure online credit card payment.

Contact
Mondial Congress & Events
Christiane Tronigger
Operngasse 20b
1040 Vienna, Austria
Tel.: +43 1 58804-0, Fax: +43 1 58804-185
e-mail: gth2018@mondial-congress.com

GENERAL CONGRESS INFORMATION

Congress Language
The official language of the congress is English. No simultaneous translation will be provided.

Registration Counter
All congress materials will be available for pick-up at the registration counters located at the entrance of the congress centre.

Preliminary Opening Hours
Tuesday, February 20 08:00 – 19:30
Wednesday, February 21 07:15 – 19:00
Thursday, February 22 07:15 – 18:30
Friday, February 23 07:15 – 12:30

Exhibition
Exhibitors can request information material from the Exhibition/Sponsoring Office:

Medizinische Ausstellungs- und Werbegesellschaft
International Exhibitions & Advertising
Andrea Etz, Simone Weinmann, Sonja Chmella
Freyung 6/3
A-1010 Vienna, Austria
Tel.: +43 1 536 63 -42, -75 or -32, Fax: +43 1 535 60 16
E-Mail: gth2018@media.co.at

Exhibition Opening Hours
Tuesday, February 20 09:00 – 20:30
Wednesday, February 21 09:00 – 18:00
Thursday, February 22 09:00 – 18:00
Friday, February 23 09:00 – 13:00

Final Programme & Abstract Publication
The final programme and abstract book will be published online at www.gth2018.org. A printed version of the final programme will be available onsite.

Name Badges
You will receive a personalised badge when collecting your registration documents. During the congress, this badge must be clearly visible at all times and grants access to the scientific sessions, commercial exhibition and official networking events. Admission to the congress will not be allowed without badge identification.
FURTHER CONGRESS INFORMATION FROM A-Z

Currency
Payment of congress-related matters such as registration fees and tickets for the networking programme will be handled in Euro (€) only.

Certificate of Attendance
For official delegates to the congress, a Certificate of Attendance is available at the registration desk.

Insurance
The congress organisers will not assume any responsibility for accidents, losses or damages, as well as for delays or modifications in the programme, caused by unforeseen circumstances. No claims for indemnification from the organisers shall arise for contractors or participants in case of cancellation, for any reason, of the entire Congress.

Delegates are advised to arrange cancellation insurance for their congress costs (i.e. registration fee, travel or accommodation costs). A cancellation insurance offered by the „Europäische Reiseversicherung“ can be booked during the online registration process. The insurance sum also covers costs incurred for services which have not been booked via Mondial Congress & Events.

Passport and Visa
Please check passport and visa requirements in due time before your departure. Three month tourist visas are issued by Austrian embassies or consulates. They can take a while to be processed, so leave enough time before departure to apply. Fees vary depending on your nationality. There are no entry requirements or restrictions on EU nationals visiting Austria. Visa information can be obtained from the Austrian Ministry of Foreign Affairs website: www.bmeia.gv.at.

Visa – Letter of Invitation
On request, the Congress Secretariat will be pleased to send letters of invitation to individual scientists. Invitations of this kind are intended to assist potential delegates to raise their travel funds or obtain visas. They do not imply any commitment or responsibility on behalf of the Congress to provide financial support. Please note that letters of invitation can only be sent after receipt of registration and payment of full registration fee. Please note that visa applications can take a while to be processed, so please send us your request for a letter of invitation in due time.

Information Updates
All congress information will be updated on a regularly basis on the congress website: www.gth2018.org

HOTEL INFORMATION

Mondial Congress & Events has secured a sufficient number of hotel rooms in 4* and 3* hotels at competitive rates. Please book your hotel room via the online registration process. In case of specific questions regarding your accommodation, please contact the congress secretariat at gth2018@mondial-congress.com.

Congress Hotels
All rates are quoted in Euro (€), per room, per night, including breakfast and all taxes.

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Price DSU</th>
<th>Price DBL</th>
<th>Distance to venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Star Standard</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astoria</td>
<td>€147,00</td>
<td>€164,00</td>
<td>20 min by public transport</td>
</tr>
<tr>
<td>Europa</td>
<td>€147,00</td>
<td>€164,00</td>
<td>20 min by public transport</td>
</tr>
<tr>
<td>3 Star</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATH Messe</td>
<td>€90,00</td>
<td>€110,00</td>
<td>4 min walking distance</td>
</tr>
<tr>
<td>Motel One Prater</td>
<td>€84,00</td>
<td>€105,12</td>
<td>5 min walking distance</td>
</tr>
</tbody>
</table>

Double Room booking
If you are sharing a room with another delegate, please book only one hotel room and provide the name of the person with whom you will be sharing.

Terms & Conditions
Hotel bookings can only be guaranteed upon receipt of the required deposit of two nights. The number of nights booked serves as a basis for your hotel invoice. Should the desired hotel no longer be available, similar accommodation will be offered. All changes or cancellations must be made in writing. Cancellation deadlines are mentioned in the “Terms and Conditions” PDF available on the first page of the online registration process.

Hotel bookings will be handled on a “first come – first served” basis. In case the requested hotel is no longer available, Mondial Congress & Events will do its utmost to offer similar accommodation. This may, however, involve a change in price. We therefore recommend early booking to ensure availability.

Group Bookings (10 or more rooms)
Group bookings are done via individual contracts. For group bookings, we kindly ask you to contact the congress secretariat to arrange details.

Contact
Mondial Congress & Events
Christiane Tronigger
Operngasse 20b
1040 Vienna, Austria
Tel.: +43 1 58804-0
Fax: +43 1 58804-185
e-mail: gth2018@mondial-congress.com
TRAVEL TO VIENNA

Access by Plane
73 international airlines offer scheduled services to Vienna. There are several daily flights between Vienna and the main European capitals and business centres. Austrian Airlines, the country’s flag carrier, connects 116 cities worldwide with Vienna and offers modern aircrafts and excellent service. Vienna International Airport at Schwechat, 19 km (12 miles) from the city centre, is state-of-the-art in every respect.

Access by Car/Coach
Austria’s expressway network reaches right into Vienna, allowing a comfortable and convenient trip to Vienna by car or coach from any point on the European continent.

Access by Train
Vienna occupies a hub position in Europe’s international railway network. Intercity and international express trains are connecting cities of all parts of Austria and all major European destinations with Vienna.

From the Airport to the City Centre and Vice Versa
Bus: At 20-minute intervals, the Vienna Airport Lines depart between 05:30 and 24:00 daily.
Cost: approx. € 7,-. Duration: approx. 20–30 min.

Train: The urban railway leaves at 10:30 min. intervals between 05:00 and 22:00 daily.
Cost: approx. € 4,-. Duration: approx. 30–40 min.

CAT: The City Airport Train runs at 30-minute intervals from 06:05 to 23:00 daily from the airport to train station „Landstrasse/Wien Mitte“.
Cost: approx. € 11,-. Duration: approx. 16min.

Public Transportation in Vienna
Reed Messe Wien (U2 Messe - Prater) as well as all hotels can easily be reached using Vienna’s efficient and modern public transport network of underground lines, trams and busses. Depending on the line in question, hours of operation are between 5:00 and 00:30 daily.

Prices
Single Trip Ticket Vienna € 2,20
24 Hours € 7,60
48 Hours € 13,30
72 Hours € 16,50

Public transportation tickets are available in Vienna Transport Authority’s ticket offices, as well as at the ticket machines in all underground stations.

TERMS & CONDITIONS

Registration and Payment
Please register online for the congress and all networking events (www.gth2018.org) as soon as possible. The deadline for pre-registrations is Friday, 16 February 2018. Registration will be confirmed once the according payment has been received by the congress office.

Cancellations must be made in writing to the congress secretariat, Mondial Congress & Events. If received before Monday, 18 December 2017, all fees, except for a cancellation charge of € 40,- will be refunded. No refunds will be made after this date. For name changes and replacements a handling fee of € 25,- will be charged. After this date, no refunds will be available. Amounts due will be reimbursed after the congress.

Changes to the Congress Programme
In the event of cancellations by speakers or other changes in the main congress programme, no full or partial refund of the registration fee can be made.

Hotel Reservations
Hotel bookings can only be guaranteed upon receipt of the required deposit of two nights. The number of nights booked serves as a basis for your hotel invoice.

All changes or cancellations must be made in writing. Cancellation deadlines are mentioned in the “Terms and Conditions” PDF available on the first page of the online registration process.

Official Networking Evening
Fees for the Official Networking Evening must be paid prior to the start of the congress. Reservations will be handled on a “first come – first served” basis.

Liability
The organizers cannot be held responsible for any personal injury, loss, damage or accident to private property, or for additional expenses incurred as a result of delays or changes in air, rail, road or other services, strikes, sickness, weather and other causes.

Mondial Congress & Events shall act as mediator only and cannot be held responsible for any loss incurred or any damage inflicted on persons or objects irrespective of whatsoever cause. The liability for transport and other service companies shall not be affected by the above. Only written agreements shall be valid. The place of jurisdiction shall be Vienna.
EXHIBITORS

The following companies will be exhibiting at the 62nd Annual Meeting of the GTH (alphabetical order)

Alexion Pharma Germany
Aspen Germany
Bayer
Biotest
BPL - Bio Products Laboratory
Chugai Pharma
CooChrom Diagnostica
CSL Behring
Daichi Sankyo
DiaSys Deutschland
DOASENSE
DSM Pentapharm
Enicor
GTH - Gesellschaft für Thrombose- und Hämostaseforschung
Grifols
Haemochrom Diagnostica
I&L Biosystems
Intersero GmbH
LFB
Mitsubishi Tanabe Pharma
Novartis Pharma
Novo Nordisk Pharma
Octapharma
Pfizer / Bristol Myers Squibb
Pfizer Pharma
Roche Pharma
Roche Diagnostics Deutschland
Roche Diagnostics
Schattauer
Sekisui Diagnostics
Shire
Siemens Healthineers
Stago
Swedish Orphan Biovitrum
TECHNOCLONE
Werfen
Wisepress

(as per printing date)

SPONSORS

The organizers of the 62nd Annual Meeting of the GTH gratefully acknowledge the support of the following companies

Platin Sponsors

CSL Behring

Gold Sponsors

octapharma

Silber Sponsors

GRIFOLS